E-LIB Suche - Ergebnisse für: Paz-Ares Gonzaga, Luis Gonzalo

1

Método de obtención de datos útiles para el diagnóstico, pr..:

Paz-Ares Gonzaga, Luis Gonzalo ; Pastor Herrera, María Dolores ; Molina Pinelo, Sonia...
https://consultas2.oepm.es/InvenesWeb/detalle?referencia=P201230874. , 2023

Link: https://idus.us.es/handl..

2

PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-target..:

Paz-Ares Rodriguez, Luis ; Felip, Enriqueta ; Ahn, Myung-Ju...
Journal of Thoracic Oncology. 19 (2024) 7 - p. e34 , 2024

Link: https://doi.org/10.1016/..

3

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-R..:

Gettinger, Scott N. ; Huber, Rudolf M. ; Kim, Dong-Wan...
JTO Clinical and Research Reports. 3 (2022) 9 - p. 100385 , 2022

Link: https://doi.org/10.1016/..

4

Trastuzumab deruxtecan in patients with metastatic non-smal..:

Smit, Egbert F ; Felip, Enriqueta ; Uprety, Dipesh...
The Lancet Oncology. 25 (2024) 4 - p. 439-454 , 2024

Link: https://doi.org/10.1016/..

5

Abemaciclib in Combination With Pembrolizumab for Stage IV ..:

Pujol, Jean-Louis ; Vansteenkiste, Johan ; Paz-Ares Rodríguez, Luis...
JTO Clinical and Research Reports. 2 (2021) 11 - p. 100234 , 2021

Link: https://doi.org/10.1016/..

6

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Foll..:

Huber, Rudolf M. ; Hansen, Karin H. ; Paz-Ares Rodríguez, Luis...
Journal of Thoracic Oncology. 15 (2020) 3 - p. 404-415 , 2020

Link: https://doi.org/10.1016/..

7

Targeting EGFR in Lung Cancer: Current Standards and Develo..:

Díaz-Serrano, Asunción ; Gella, Pablo ; Jiménez, Elisabeth..
Drugs. 78 (2018) 9 - p. 893-911 , 2018

Link: https://doi.org/10.1007/..

8

Spanish Society of Medical Oncology consensus for the use o..:

on behalf of the Spanish Society of Medical Oncology (SEOM) ; Carrato Mena, Alfredo ; Paz-Ares Rodríguez, Luis...
Clinical and Translational Oncology. 11 (2009) 7 - p. 446-454 , 2009

Link: https://doi.org/10.1007/..

9

PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemot..:

Badin, Firas ; Carbone, David P. ; Ciuleanu, Tudor-Eliade...
Journal of Thoracic Oncology. 19 (2024) 7 - p. e51 , 2024

Link: https://doi.org/10.1016/..

10

First-line Avelumab plus Chemotherapy in Patients with Adva..:

Wheatley, Duncan A. ; Berardi, Rossana ; Climent Duran, Miguel A....
Cancer Research Communications. 4 (2024) 6 - p. 1609-1619 , 2024

Link: https://doi.org/10.1158/..

11

Tepotinib in patients with non-small cell lung cancer with ..:

Le, Xiuning ; Paz-Ares, Luis G. ; Van Meerbeeck, Jan...
Cell Reports Medicine. 4 (2023) 11 - p. 101280 , 2023

Link: https://doi.org/10.1016/..

12

Systemic and Intracranial Outcomes With First-Line Nivoluma..:

Reck, Martin ; Ciuleanu, Tudor-Eliade ; Lee, Jong-Seok...
Journal of Thoracic Oncology. 18 (2023) 8 - p. 1055-1069 , 2023

Link: https://doi.org/10.1016/..

13

Response to the Letter to the Editor Titled "First-Line Niv..:

Paz-Ares, Luis G. ; Carbone, David P.
Journal of Thoracic Oncology. 18 (2023) 9 - p. e102-e103 , 2023

Link: https://doi.org/10.1016/..

14

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Vers..:

Paz-Ares, Luis G. ; Ciuleanu, Tudor-Eliade ; Cobo, Manuel...
Journal of Thoracic Oncology. 18 (2023) 2 - p. 204-222 , 2023

Link: https://doi.org/10.1016/..

15

Safety of First-Line Nivolumab Plus Ipilimumab in Patients ..:

Paz-Ares, Luis G. ; Ciuleanu, Tudor-Eliade ; Pluzanski, Adam...
Journal of Thoracic Oncology. 18 (2023) 1 - p. 79-92 , 2023

Link: https://doi.org/10.1016/..